In vitro evaluation of colistin and ceftazidime avibactam activity against multi-drug resistant klebsiella pneumoniae isolates

Year 2025, Volume: 42 Issue: 2, 159 - 164, 30.06.2025

Tuğba Avan Mutlu

Abstract

This study aimed to evaluate the in vitro effectiveness of colistin and ceftazidime-avibactam (CZA) antibiotics against multidrug-resistant (MDR) Klebsiella pneumoniae isolates. The study included 54 clinical isolates sent to the Medical Microbiology Laboratory of Kirsehir Education and Research Hospital between 2022 and 2023, which were resistant to multiple drugs in routine antibiotic susceptibility tests. Colistin susceptibility was evaluated using the microdilution method, while CZA susceptibility was assessed using the disk diffusion method according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. It was determined that 31.4% of the isolates were resistant to colistin, and 22.2% were resistant to CZA. No isolates were resistant to both antibiotics. Statistical analyses did not reveal a significant relationship between antibiotic susceptibility and gender, age, underlying disease, and sample type (p>0.05). However, colistin resistance has been found to be higher in intensive care units, whereas resistance to CZA has significantly increased in internal medicine units (p =0.025). The study's findings indicate that colistin and CZA may be important in treating multidrug-resistant K. pneumoniae infections. CZA provides an effective alternative for colistin-resistant isolates, while colistin is an effective alternative for CZA-resistant isolates. However, to enhance the efficacy of these agents, larger-scale studies and ongoing monitoring of resistance mechanisms are necessary.

Keywords

Colistin , Ceftazidime Avibactam , Klebsiella Pneumoniae

Ethical Statement

It was obtained from Kirsehir Ahi Evran University Faculty of Medicine, Non-Interventional Clinical Research Ethics Committee with the decision number 2024-4/15 dated 06/02/2024.

Supporting Institution

No financial support was received for the project.

References

• Temel A, Tekintaş Y, Hoşgör Limoncu M, Cilli F. Klinik Klebsiella pneumoniae ve Acinetobacter baumannii izolatlarında imipenem direncinin hızlı tespitinde AST Fast ES/NF agar besiyerinin değerlendirilmesi. J Fac Pharm Ankara Univ. 2023; 47(2): 430-437.
• Poudyal A, Howden BP, Bell JM, Gao W, Owen RJ, Turnidge JD, et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2008; 62(6): 1311-8.
• Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012; 18(3): 268-81.
• Shirley M. Ceftazidime-avibactam: a review in treating serious gram-negative bacterial infections. Drugs. 2018; 78:675-92.
• Hoşbul T, Aydogan CN, Kaya S, Bedir O, Gümral R, Albay A. Karbapenem dirençli Klebsiella pneumoniae klinik izolatlarına karşı seftazidim-avibaktam ve kolistinin in vitro etkinliği. Mikrobiyol Bul. 2022; 56(2): 218-29.
• Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011; 17(10): 1791-8.
• World Health Organization (WHO). Antimicrobial resistance: global report on surveillance. Geneva: WHO; 2020.
• Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. Antibiotic treatment of infections due to carbapenem- resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother. 2014; 58(2): 654-63.
• Gatti M, Pascale R, Cojutti PG, Rinaldi M, Ambretti S, Conti M, et al. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia. Int J Antimicrob Agents. 2023; 61(1): 106699.
• Wang Y, Wang J, Wang R, Cai Y. Resistance to ceftazidime–avibactam and underlying mechanisms. J Glob Antimicrob Resist. 2020; 22: 18-27.
• Novović K, Jovčić B. Colistin resistance in Acinetobacter baumannii: molecular mechanisms and epidemiology. Antibiotics. 2023; 12(3): 516.
• Jayol A, Poirel L, Nordmann P. Colistin resistance in Enterobacteriaceae: the importance of assessing MICs. Clin Microbiol Infect. 2016; 22(5): 461-9.
• Hackel M, Kazmierczak KM, Hoban DJ, Biedenbach DJ, Bouchillon SK, de Jonge BL, Stone GG. Assessment of the in vitro activity of ceftazidime-avibactam against multidrug-resistant Klebsiella spp. collected in the INFORM global surveillance study, 2012 to 2014. Antimicrobial Agents and Chemotherapy. 2016; 60(8): 4677-4683.
• van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, et al. Antibacterial Resistance Leadership Group. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis. 2018; 66(2): 163-171.
• Almangour TA, Ghonem L, Aljabri A, Alruwaili A, Al Musawa M, Damfu N, et al. Ceftazidime-avibactam versus colistin for the treatment of infections due to carbapenem-resistant Enterobacterales: a multicenter cohort study. Infection and drug resistance. 2022; 211-221.
• Sree RA, Gupta A, Gupta N, Veturi S, Reddy LSK, Begum M, Shravani E, et al. Ceftazidime-avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-resistant Klebsiella pneumoniae nosocomial Infections (CAPRI study): a retrospective cohort study from South India. Infection. 2024; 52(2): 429-437.
• Ulusal Antimikrobiyal Direnç Sürveyans Sistemi 2016 Yıllık Raporu, Türkiye Halk Sağlığı Kurumu, Sağlık Bakanlığı, Ankara.
• Özkul Koçak C, Hazirolan G. Karbapeneme dirençli Klebsiella pneumoniae klinik izolatlarında kolistin direnci. Turk Mikrobiyol Cem Derg. 2019; 49(1).
• Kaya F, Ölçü M. Yoğun bakım ünitelerinde çoklu ilaca dirençli Klebsiella pneumoniae, Escherichia coli ve Pseudomonas aeruginosa Suşlarında Seftazidim-Avibactam direnç oranlarının değerlendirilmesi. 2024; 29(1):45- 51.
• Jayol A, Nordmann P, Poirel L, Dbois V. Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy. 2018; 73(2), 542-544.
• Mert A, Derin O, Akalın H, Dumlu R, Gündeş S, Zengin R, Ergönül Ö. Multicenter evaluation of ceftazidime-avibactam use in carbapenem-resistant Klebsiella pneumoniae bloodstream infections in OXA-48 endemic regions. Scientific Reports. 2024; 14(1), 26337.
• Wu Y, Yu W, Chu X, Zhang J, Jia P, Liu X, Yang Q. Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant Klebsiella pneumoniae. Microbiology Spectrum. 2024; 12(6), e00107-24.
• Wang F, Zhou Q, Yang X, Bai Y, Cui J. Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment. PLoS One. 2021; 16(10), e0258426.
• Borjan J, Meyer KA, Shields RK, Wenzler E. Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo Galleria mellonella survival model analysis. International Journal of Antimicrobial Agents. 2020; 55(1), 105852.